THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Destiny Pharma plc
(“Destiny” or the “Company”)
Result of General Meeting
Total Voting Rights
Brighton, United Kingdom ‐ 28 March 2022 ‐ Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that, at the General Meeting held earlier today, all resolutions proposed were duly passed by shareholders on a poll.
Accordingly, the Company has raised total gross proceeds of approximately £6.45 million from the Fundraising and has allotted a total of 12,909,007 New Shares. Admission of the 12,909,007 New Shares, comprised of the Placing Shares, the Subscription Shares and the Open Offer Shares, is expected to occur on 29 March 2022.
Following Admission on 29 March 2022, the Company’s issued ordinary share capital will comprise 73,307,105 Ordinary Shares, none of which are held in treasury. The above figure of 73,307,0105 may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
A summary of the votes received for the General Meeting will be made available on the Company’s website at www.destinypharma.com.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 March 2022.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
+44 (0) 208 078 4357
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
MC Services AG (Joint Broker)
Anne Hennecke / Andreas Burckhardt
For full press release, please click here